Deimmunized anti c-Met humanized antibodies and uses thereof
A deimmunized anti c-Met humanized antibody and a pharmaceutical composition including the same, and method for the prevention and treatment of cancer.
1. An anti c-Met humanized antibody comprising a heavy chain variable region comprising any one of SEQ ID NOs: 1-5, and a light chain variable region comprising any one of SEQ ID NOs: 6-9.
2. The anti c-Met humanized antibody of claim 1 , wherein the heavy chain variable region comprises SEQ ID NO: 2 and the light chain variable region comprises SEQ ID NO: 7.
3. The anti c-Met humanized antibody of claim 1 , wherein the heavy chain variable region comprising SEQ ID NO: 2, and the light chain variable region comprises SEQ ID NO: 9.
4. The anti c-Met humanized antibody of claim 1 , wherein the heavy chain variable region comprises SEQ ID NO: 5 and the light chain variable region comprises SEQ ID NO: 7.
5. The anti c-Met humanized antibody of claim 1 , wherein the antibody specifically binds c-Met from a human or monkey, a mouse, or a rat.
6. The anti c-Met humanized antibody of claim 1 , wherein the anti c-Met humanized antibody is a monoclonal antibody.
7. The anti c-Met humanized antibody of claim 1 , wherein the anti c-Met humanized antibody is less immunogenic than trastuzumab.
8. The anti c-Met humanized antibody of claim 1 , wherein the anti c-Met humanized antibody is an antigen binding fragment selected from the group consisting of scFv, (scFv) 2 , Fab, Fab′ and F(ab′) 2 .
9. A pharmaceutical composition comprising an anti c-Met humanized antibody of claim 1 and a pharmaceutically acceptable support, diluent, or excipient.
10. The pharmaceutical composition of claim 9 , wherein the anti c-Met humanized antibody comprises a heavy chain variable region comprising SEQ ID NO: 2 and a light chain variable region comprising SEQ ID NO: 7.
11. The pharmaceutical composition of claim 9 , wherein the anti c-Met humanized antibody comprises a heavy chain variable region comprising SEQ ID NO: 2 and a light chain variable region comprising SEQ ID NO: 9.
12. The pharmaceutical composition of claim 9 , wherein the anti c-Met humanized antibody comprises a heavy chain variable region comprising SEQ ID NO: 5 and a light chain variable region comprising SEQ ID NO: 7.